




RealRate

PHARMACEUTICAL 2019

Statera Biopharma Inc.
Rank 190 of 363





RealRate

PHARMACEUTICAL 2019

Statera Biopharma Inc. Rank 190 of 363



The relative strengths and weaknesses of Statera Biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Statera Biopharma Inc. compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 83% points. The greatest weakness of Statera Biopharma Inc. is the variable Expenses, reducing the Economic Capital Ratio by 71% points.

The company's Economic Capital Ratio, given in the ranking table, is 92%, being 55% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	4,476
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	912
Liabilities, Non-Current	8.5
Other Assets	30
Other Compr. Net Income	0.56
Other Expenses	0
Other Liabilities	0
Other Net Income	2,231
Other Revenues	0
Property and Equipment	28
Research and Development	3,619
Selling, General and Administrative Expense	2,319

Output Variable	Value in 1000 USD
Assets	4,534
Liabilities	920
Expenses	5,938
Revenues	0
Stockholders Equity	3,614
Net Income	-3,707
Comprehensive Net Income	-3,707
Economic Capital Ratio	92%